Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2737 single and multiple ascending dose study in healthy male volunteers
NL-OMON42886Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG2737 in cystic fibrosis (CF) (8 arms), sponsored by Galapagos NV. Primary endpoints: Safety and tolerability after single ascending doses and Safety and tolerability after multiple ascending doses. Started Nov 2016; status: active, not recruiting.
02
Drugs
GLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON42886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42886.